Osteoprotegerin rich tumor microenvironment: implications in breast cancer
Open Access
- 8 April 2016
- journal article
- review article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (27) , 42777-42791
Abstract
Osteoprotegerin rich tumor microenvironment: implications in breast cancerKeywords
This publication has 101 references indexed in Scilit:
- Marked elevation in plasma osteoprotegerin constitutes an early and consistent feature of cerebral malariaThrombosis and Haemostasis, 2016
- Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation CarriersEBioMedicine, 2015
- Osteoprotegerin is up-regulated in pancreatic cancers and correlates with cancer-associated new-onset diabetesBioScience Trends, 2014
- Osteoprotegerin induces morphological and functional alterations in mouse pancreatic isletsMolecular and Cellular Endocrinology, 2011
- Denosumab‐mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patientsArthritis Care & Research, 2010
- Syndecan-1 Is Involved in Osteoprotegerin-Induced Chemotaxis in Human Peripheral Blood MonocytesThe Journal of Clinical Endocrinology & Metabolism, 2005
- Metastasis to bone: causes, consequences and therapeutic opportunitiesNature Reviews Cancer, 2002
- Protein Expression and Functional Difference of Membrane-Bound and Soluble Receptor Activator of NF-κB Ligand: Modulation of the Expression by Osteotropic Factors and CytokinesBiochemical and Biophysical Research Communications, 2000
- Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation1Endocrinology, 1999
- A major nucleolar protein, nucleolin, induces chromatin decondensation by binding to histone HlEuropean Journal of Biochemistry, 1988